On the Record

"A drug may have strong utilization in one indication, driving meaningful rebate revenue, but weaker utilization in another indication. Payers won't be handcuffed based upon performance in a single indication and can maximize rebate potential across multiple indications."

— Andrew Cournoyer, R.Ph., vice president, director – payer access solutions at Precision for Value, talked with AIS's RADAR on Specialty Pharmacy about the transition to indication-based formularies in Part D.